Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.34 |
| ▸ | ABL1 | P00519 | 4/20 | 0.34 |
| ▸ | EGFR | P00533 | 4/20 | 0.34 |
| ▸ | HCK | P08631 | 4/20 | 0.34 |
| ▸ | SRC | P12931 | 4/20 | 0.34 |
| ▸ | KDR | P35968 | 4/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.34 |
| ▸ | MTOR | P42345 | 4/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 4/20 | 0.34 |
| ▸ | PRKDC | P78527 | 4/20 | 0.34 |
| ▸ | BTK | Q06187 | 3/20 | 0.32 |
| ▸ | ESR1 | P03372 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16611222 | 0.89 | ESR1 (0.36) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL16610926 | 0.89 | BTK (0.33) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL16611027 | 0.88 | BTK (0.31) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL16611155 | 0.86 | BTK (0.31) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL16611256 | 0.81 | PIK3CD (0.37) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL16611047 | 0.79 | EGFR (0.36) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL16611520 | 0.76 | PTGER1 (0.32) | — | |
| SCHEMBL18052600 | 0.75 | PIK3CD (0.37) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL16611144 | 0.75 | JAK2 (0.40) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL16611254 | 0.74 | JAK1 (0.34) | PIK3CDABL1EGFRHCKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | PIK3CD 1337/4885ABL1 1046/4885EGFR 4532/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | PIK3CD 1337/4885ABL1 1046/4885EGFR 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.